These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
473 related items for PubMed ID: 19264579
1. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Bygum A, Andersen KE, Mikkelsen CS. Eur J Dermatol; 2009; 19(2):147-51. PubMed ID: 19264579 [Abstract] [Full Text] [Related]
2. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Kreuz W, Martinez-Saguer I, Aygören-Pürsün E, Rusicke E, Heller C, Klingebiel T. Transfusion; 2009 Sep; 49(9):1987-95. PubMed ID: 19497056 [Abstract] [Full Text] [Related]
3. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtułowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T, Grivcheva-Panovska V, Kiessling PC, Keinecke HO, Bernstein JA. J Allergy Clin Immunol; 2009 Oct; 124(4):801-8. PubMed ID: 19767078 [Abstract] [Full Text] [Related]
6. Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study. Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, von Hentig N, Klingebiel T, Kreuz W. Transfusion; 2010 Feb; 50(2):354-60. PubMed ID: 19788511 [Abstract] [Full Text] [Related]
7. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study. Moldovan D, Reshef A, Fabiani J, Kivity S, Toubi E, Shlesinger M, Triggiani M, Montinaro V, Cillari E, Realdi G, Cancian M, Visscher S, Zanichelli A, Relan A, Cicardi M. Clin Exp Allergy; 2012 Jun; 42(6):929-35. PubMed ID: 22909164 [Abstract] [Full Text] [Related]
11. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study. Zanichelli A, Azin GM, Cristina F, Vacchini R, Caballero T. Orphanet J Rare Dis; 2018 Apr 10; 13(1):51. PubMed ID: 29631595 [Abstract] [Full Text] [Related]
14. Home Therapy with Plasma-Derived C1 Inhibitor: A Strategy to Improve Clinical Outcomes and Costs in Hereditary Angioedema. Petraroli A, Squeglia V, Di Paola N, Barbarino A, Bova M, Spanò R, Marone G, Triggiani M. Int Arch Allergy Immunol; 2015 Apr 10; 166(4):259-66. PubMed ID: 25924832 [Abstract] [Full Text] [Related]
15. Training hereditary angioedema patients to self-administer intravenous C1 esterase inhibitor concentrate. Shapiro RS, Zacek L. J Infus Nurs; 2014 Apr 10; 37(4):284-90. PubMed ID: 24983261 [Abstract] [Full Text] [Related]
17. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Schneider L, Hurewitz D, Wasserman R, Obtulowicz K, Machnig T, Moldovan D, Reshef A, Craig TJ. Pediatr Allergy Immunol; 2013 Feb 10; 24(1):54-60. PubMed ID: 23173714 [Abstract] [Full Text] [Related]
18. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Kreuz W, Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Heller C, Klingebiel T. Transfusion; 2012 Jan 10; 52(1):100-7. PubMed ID: 21756262 [Abstract] [Full Text] [Related]
19. Patients perception of self-administrated medication in the treatment of hereditary angioedema. Wang A, Fouche A, Craig TJ. Ann Allergy Asthma Immunol; 2015 Aug 10; 115(2):120-5. PubMed ID: 26118352 [Abstract] [Full Text] [Related]